Ye Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ye Xu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Cong Tan
Institutes of Biomedical Sciences, Fudan University, Shanghai, China
6 shared publications - Guoxiang Cai
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
6 shared publications Qinghua Xu
6 shared publications- Shujuan Ni
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
6 shared publications - Xia Meng
Department of Basic Theory of Traditional Chinese Medicine, School of Basic Medicine, Guangxi University of Chinese Medicine, Nanning City, Guangxi, China
6 shared publications - Xiang Du
Institutes of Biomedical Sciences, Fudan University, Shanghai, China
6 shared publications
Latest Publications
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e186027b
P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION:A MULTICENTER, RANDOMIZED PHASE III TRIAL
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e186027b
Open AccessP1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION:A MULTICENTER, RANDOMIZED PHASE III TRIAL
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Gas1 Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma
Endogenous expression level of Gas1 in six colon cancer cells demonstrated by Western blot (A) and RT-PCR (B).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Gas1 Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma
Endogenous expression level of Gas1 in six colon cancer cells demonstrated by Western blot (A) and RT-PCR (B).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure Legend from Gas1 Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure Legend from Gas1 Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 65K, Association between samples' characteristics and signature prediction outcomes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 65K, Association between samples' characteristics and signature prediction outcomes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 151K, On the heat map, red colors indicate genes upregulated and green colors indicate genes downregulated. Among the 263 genes, 179 were up-regulated and 84 were down-regulated in the cancer patients, respectively. On the hierarchical clustering diagram, green bars represent controls and red bars represent CRC patients. Two hundred samples appeared to be distributed into two major separate clusters with few overlaps, revealing distinct gene expression patterns between the CRC group and the Control group.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 151K, On the heat map, red colors indicate genes upregulated and green colors indicate genes downregulated. Among the 263 genes, 179 were up-regulated and 84 were down-regulated in the cancer patients, respectively. On the hierarchical clustering diagram, green bars represent controls and red bars represent CRC patients. Two hundred samples appeared to be distributed into two major separate clusters with few overlaps, revealing distinct gene expression patterns between the CRC group and the Control group.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 70K, Signature genes enriched in Gene Ontology and KEGG pathway.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 70K, Signature genes enriched in Gene Ontology and KEGG pathway.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 58K, The table list primer sequences for 18 signature genes and 3 reference genes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 58K, The table list primer sequences for 18 signature genes and 3 reference genes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 65K, Association between samples' characteristics and signature prediction outcomes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
PDF file - 65K, Association between samples' characteristics and signature prediction outcomes.
- Open Access
- 7 November 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-13
Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study
Background: Radiotherapy is an important treatment for patients with stage III/IV non-small cell lung cancer (NSCLC), and due to its high incidence of radiation pneumonitis, it is essential to identify high-risk people as early as possible. The present work investigates the value of the application of different phase data throughout the radiotherapy process in analyzing risk of grade ≥ 2 radiation pneumonitis in stage III/IV NSCLC. Furthermore, the phase data fusion was gradually performed with the radiotherapy timeline to develop a risk assessment model. Methods: This study retrospectively collected data from 91 stage III/IV NSCLC cases treated with Volumetric modulated arc therapy (VMAT). Patient data were collected according to the radiotherapy timeline for four phases: clinical characteristics, radiomics features, radiation dosimetry parameters, and hematological indexes during treatment. Risk assessment models for single-phase and stepwise fusion phases were established according to logistic regression. In addition, a nomogram of the final fusion phase model and risk classification system was generated. Receiver operating characteristic (ROC), decision curve, and calibration curve analysis were conducted to internally validate the nomogram to analyze its discrimination. Results: Smoking status, PTV and lung radiomics feature, lung and esophageal dosimetry parameters, and platelets at the third week of radiotherapy were independent risk factors for the four single-phase models. The ROC result analysis of the risk assessment models created by stepwise phase fusion were: (area under curve [AUC]: 0.67,95% confidence interval [CI]: 0.52–0.81), (AUC: 0.82,95%CI: 0.70–0.94), (AUC: 0.90,95%CI: 0.80–1.00), and (AUC:0.90,95%CI: 0.80–1.00), respectively. The nomogram based on the final fusion phase model was validated using calibration curve analysis and decision curve analysis, demonstrating good consistency and clinical utility. The nomogram-based risk classification system could correctly classify cases into three diverse risk groups: low-(ratio:3.6%; 0 < score < 135), intermediate-(ratio:30.7%, 135 < score < 160) and high-risk group (ratio:80.0%, score > 160). Conclusions: In our study, the risk assessment model makes it easy for physicians to assess the risk of grade ≥ 2 radiation pneumonitis at various phases in the radiotherapy process, and the risk classification system and nomogram identify the patient’s risk level after completion of radiation therapy.
- 7 November 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-13
Open AccessRisk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study
Background: Radiotherapy is an important treatment for patients with stage III/IV non-small cell lung cancer (NSCLC), and due to its high incidence of radiation pneumonitis, it is essential to identify high-risk people as early as possible. The present work investigates the value of the application of different phase data throughout the radiotherapy process in analyzing risk of grade ≥ 2 radiation pneumonitis in stage III/IV NSCLC. Furthermore, the phase data fusion was gradually performed with the radiotherapy timeline to develop a risk assessment model. Methods: This study retrospectively collected data from 91 stage III/IV NSCLC cases treated with Volumetric modulated arc therapy (VMAT). Patient data were collected according to the radiotherapy timeline for four phases: clinical characteristics, radiomics features, radiation dosimetry parameters, and hematological indexes during treatment. Risk assessment models for single-phase and stepwise fusion phases were established according to logistic regression. In addition, a nomogram of the final fusion phase model and risk classification system was generated. Receiver operating characteristic (ROC), decision curve, and calibration curve analysis were conducted to internally validate the nomogram to analyze its discrimination. Results: Smoking status, PTV and lung radiomics feature, lung and esophageal dosimetry parameters, and platelets at the third week of radiotherapy were independent risk factors for the four single-phase models. The ROC result analysis of the risk assessment models created by stepwise phase fusion were: (area under curve [AUC]: 0.67,95% confidence interval [CI]: 0.52–0.81), (AUC: 0.82,95%CI: 0.70–0.94), (AUC: 0.90,95%CI: 0.80–1.00), and (AUC:0.90,95%CI: 0.80–1.00), respectively. The nomogram based on the final fusion phase model was validated using calibration curve analysis and decision curve analysis, demonstrating good consistency and clinical utility. The nomogram-based risk classification system could correctly classify cases into three diverse risk groups: low-(ratio:3.6%; 0 < score < 135), intermediate-(ratio:30.7%, 135 < score < 160) and high-risk group (ratio:80.0%, score > 160). Conclusions: In our study, the risk assessment model makes it easy for physicians to assess the risk of grade ≥ 2 radiation pneumonitis at various phases in the radiotherapy process, and the risk classification system and nomogram identify the patient’s risk level after completion of radiation therapy.